Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial

Key Points

• HIV rebound occurs after antiretroviral therapy interruption, and long-acting broadly neutralising antibodies can help delay this.
• The trial uncovers that long-acting bNAbs support extended periods of viral control following treatment interruptions, with notable implications for ART-free remission.
• Double-blind randomized placebo-controlled trial assesses the efficacy of bNAbs on HIV control in early-stage infected individuals, demonstrating promising results.
• These findings highlight the potential for new therapeutic strategies; further studies are needed for broader applicability in HIV management.